Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition

Fig. 4

Inter-relationship of BMI, gender, serum creatinine and Durable Clinical Benefit (DCB) (a-f): Panel a shows the predominant male gender driven association of overweight/Class-I obesity with a higher probability of achieving DCB (red) compared to normal weight/underweight patients and Class-II/III obese patients who had lower probability of DCB (blue). Panel b shows that patients who had serum creatinine < 0.9 mg/dL had lower probability of DCB and the obesity paradox pattern (red) was largely attenuated. Panel c shows that the paradox was attenuated for both genders for lower serum creatinine levels (< 0.9 mg/dL). Panel d shows that findings from Panel c were noted for both anti-PD-1 based monotherapy and combination therapy. Panel e shows the relationship of serum creatinine with probability of achieving DCB. Panel f shows the distribution of serum creatinine among patients with and without DCB

Back to article page